Literature DB >> 15710809

Two-year follow-up of a 6-month randomized trial of atropine vs patching for treatment of moderate amblyopia in children.

Michael X Repka1, David K Wallace, Roy W Beck, Raymond T Kraker, Eileen E Birch, Susan A Cotter, Sean Donahue, Donald F Everett, Richard W Hertle, Jonathan M Holmes, Graham E Quinn, Mitchell M Scheiman, David R Weakley.   

Abstract

OBJECTIVE: To compare patching and atropine sulfate as treatments for moderate amblyopia in children 18 months after completion of a 6-month randomized trial.
METHODS: In a randomized, multicenter (47 sites) clinical trial, 419 children younger than 7 years with amblyopia (20/40 to 20/100 in the affected eye) were assigned to receive either patching or atropine eye drops for 6 months. Between 6 months and 2 years, treatment was at the discretion of the investigator. Main Outcome Measure Visual acuity in the amblyopic eye and sound eye after 2 years.
RESULTS: At 2 years, visual acuity in the amblyopic eye improved from baseline a mean of 3.7 lines in the patching group and 3.6 lines in the atropine group. The difference in visual acuity between treatment groups was small: 0.01 logMAR (95% confidence interval, -0.02 to 0.04). In both treatment groups, the mean amblyopic eye acuity was approximately 20/32, 1.8 lines worse than the mean sound eye acuity, which was approximately 20/20.
CONCLUSIONS: Atropine or patching for 6 months followed by best clinical care until 2 years produced similar improvement of moderate amblyopia in children between 3 and 7 years of age at enrollment. However, on average the amblyopic eye acuity was still approximately 2 lines worse than the sound eye.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15710809     DOI: 10.1001/archopht.123.2.149

Source DB:  PubMed          Journal:  Arch Ophthalmol        ISSN: 0003-9950


  51 in total

1.  Binocular iPad treatment for amblyopia in preschool children.

Authors:  Eileen E Birch; Simone L Li; Reed M Jost; Sarah E Morale; Angie De La Cruz; David Stager; Lori Dao; David R Stager
Journal:  J AAPOS       Date:  2015-02       Impact factor: 1.220

2.  Structural and functional comparison of the persistent and resolved amblyopia.

Authors:  Betul Tugcu; Bilge Araz-Ersan; Ezgi Tuna Erdogan; Hatice Tarakcioglu; Cigdem Coskun; Ulviye Yigit; Sacit Karamursel
Journal:  Doc Ophthalmol       Date:  2013-12-18       Impact factor: 2.379

3.  The effect of amblyopia therapy on ocular alignment.

Authors:  Michael X Repka; Jonathan M Holmes; B Michele Melia; Roy W Beck; Matthew D Gearinger; Susanna M Tamkins; David T Wheeler
Journal:  J AAPOS       Date:  2005-12       Impact factor: 1.220

Review 4.  [The latest on amblyopia treatment].

Authors:  O Ehrt
Journal:  Ophthalmologe       Date:  2008-05       Impact factor: 1.059

Review 5.  The treatment of amblyopia: current practice and emerging trends.

Authors:  Eleni Papageorgiou; Ioannis Asproudis; Gail Maconachie; Evangelia E Tsironi; Irene Gottlob
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2019-01-31       Impact factor: 3.117

6.  Conventional occlusion versus pharmacologic penalization for amblyopia.

Authors:  Tianjing Li; Riaz Qureshi; Kate Taylor
Journal:  Cochrane Database Syst Rev       Date:  2019-08-28

7.  The effect on refractive error of unilateral atropine as compared with patching for the treatment of amblyopia.

Authors:  Michael X Repka; Michele Melia; Maya Eibschitz-Tsimhoni; Richard London; Elbert Magoon
Journal:  J AAPOS       Date:  2007-06       Impact factor: 1.220

8.  Amblyopia therapy in Asian children: factors affecting visual outcome and parents' perception of children's attitudes towards amblyopia treatment.

Authors:  Swati Handa; Audrey Chia
Journal:  Singapore Med J       Date:  2018-11-29       Impact factor: 1.858

9.  Rethinking amblyopia 2020.

Authors:  Dennis M Levi
Journal:  Vision Res       Date:  2020-08-28       Impact factor: 1.886

10.  Current concepts in the management of amblyopia.

Authors:  Blanca Ruiz de Zárate; Jaime Tejedor
Journal:  Clin Ophthalmol       Date:  2007-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.